Component I ‘Enabling pre-emptive testing’ would like to inform all partners that the IT decision support infrastructure works in all three intervention-first implementation sites! This includes for example that the genotyping platforms and card printers are operational and the genotype-haplotype-phenotype translation table has been approved. In addition, all involved staff members are being trained in pharmacogenomics by e-learning.
Component II ‘Implementation of pre-emptive testing’ would like to add that ethical approval of the PREPARE study protocol is in place in all three intervention-first implementation sites, as well as three control-first implementation sites. Also the 4th site has obtained approval to start including control patients. The eCRF, LIM tool and SOPs are almost ready and functional. The final SOPs will be placed in the members repository of the U-PGx website under the heading “PREPARE Study Documents” this week.
This means that all clinical sites can start to include patients on March 20th! Be ready! The first experiences with including patients will be shared in Vienna.